GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (TSX:CSCI) » Definitions » Cyclically Adjusted PB Ratio

Cosciens Biopharma (TSX:CSCI) Cyclically Adjusted PB Ratio : 0.34 (As of Jun. 19, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma Cyclically Adjusted PB Ratio?

As of today (2025-06-19), Cosciens Biopharma's current share price is C$4.82. Cosciens Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was C$14.09. Cosciens Biopharma's Cyclically Adjusted PB Ratio for today is 0.34.

The historical rank and industry rank for Cosciens Biopharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSX:CSCI' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.27   Med: 3.83   Max: 132.34
Current: 0.34

During the past years, Cosciens Biopharma's highest Cyclically Adjusted PB Ratio was 132.34. The lowest was 0.27. And the median was 3.83.

TSX:CSCI's Cyclically Adjusted PB Ratio is ranked better than
76.69% of 682 companies
in the Biotechnology industry
Industry Median: 1.515 vs TSX:CSCI: 0.34

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cosciens Biopharma's adjusted book value per share data for the three months ended in Mar. 2025 was C$4.629. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$14.09 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cosciens Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cosciens Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma Cyclically Adjusted PB Ratio Chart

Cosciens Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.14 3.04 2.33 0.63 0.28

Cosciens Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.45 0.37 0.28 0.31

Competitive Comparison of Cosciens Biopharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cosciens Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Cyclically Adjusted PB Ratio falls into.


;
;

Cosciens Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cosciens Biopharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.82/14.09
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cosciens Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=4.629/129.1809*129.1809
=4.629

Current CPI (Mar. 2025) = 129.1809.

Cosciens Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201506 2.113 100.500 2.716
201509 2.850 100.421 3.666
201512 5.277 99.947 6.820
201603 6.313 101.054 8.070
201606 7.294 102.002 9.238
201609 12.138 101.765 15.408
201612 12.581 101.449 16.020
201703 13.071 102.634 16.452
201706 13.611 103.029 17.066
201709 13.389 103.345 16.736
201712 12.839 103.345 16.049
201803 12.565 105.004 15.458
201806 12.455 105.557 15.242
201809 12.604 105.636 15.413
201812 12.596 105.399 15.438
201903 12.491 106.979 15.083
201906 12.332 107.690 14.793
201909 12.123 107.611 14.553
201912 12.325 107.769 14.774
202003 12.644 107.927 15.134
202006 13.337 108.401 15.894
202009 13.397 108.164 16.000
202012 13.329 108.559 15.861
202103 13.500 110.298 15.811
202106 13.729 111.720 15.875
202109 14.317 112.905 16.381
202112 15.182 113.774 17.238
202203 16.159 117.646 17.743
202206 16.699 120.806 17.857
202209 16.837 120.648 18.028
202212 17.508 120.964 18.697
202303 17.548 122.702 18.475
202306 16.796 124.203 17.469
202309 16.140 125.230 16.649
202312 15.271 125.072 15.773
202403 14.086 126.258 14.412
202406 11.739 127.522 11.892
202409 8.684 127.285 8.813
202412 5.969 127.364 6.054
202503 4.629 129.181 4.629

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cosciens Biopharma  (TSX:CSCI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cosciens Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
Executives
Dennis Turpin Director
Gilles Gagnon Director

Cosciens Biopharma Headlines

From GuruFocus